DHR Danaher Corp

$183.67
$0.00 (0.00%)

DHR Stock Analysis Overview

What this means: Danaher Corp (DHR) gets an Overall Rank of 64, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. DHR's 64 means that it ranks higher than 64% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full DHR report

Danaher Corp (DHR) Analyst Forecast

Next 12 months ➝Current Price$183.6752-week High$187.1952-week Low$119.60MEAN$175.42-4.49%HIGH$190.00+3.45%LOW$154.00-16.15%
  • Last Price$183.67
  • Previous Close$183.67
  • Change $0.00
  • Open$185.53
  • Volume1,956,000
  • Avg. Volume (100-day)3,609,374
  • Market Capitalization$130B
  • Days Range $182.80 - $185.85
  • 52-week Range $119.60 - $187.19
  • Dividend Yield0.39%
  • Ex. Dividend Date06/25/2020
  • P-E42.2
  • EPS4.4
  • Earnings Date07/16/2020
  • SectorHealthcare
  • IndustryDiagnostics & Research
  • Avg. Analyst Rec.
  • Beta0.737
  • PEG Ratio4.15
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in four segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which adds to its life sciences segment.